Search Medical Condition
Please enter condition
Please choose location from dropdown

Addictions Clinical Trials

A listing of Addictions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (312) clinical trials

Abuse Liability of Reduced Nicotine Content Cigarettes Within a Complex Tobacco Marketplace

Tobacco regulatory policies can have unanticipated consequences; therefore, methods that would permit prospective estimates of the effects of potential tobacco regulations are necessary for the development of tobacco regulatory science. The goal of this project is to experimentally assess how smokers purchase and consume reduced-nicotine cigarettes. In experiment 1, we ...

Phase N/A

Effect of Cigarette Pack Warnings and Packaging Among Young Adult Smokers

The study includes young adult smokers ages 18 to 30. Eligible participants are young adults ages 18 to 30 years inclusive who report smoking at least 100 lifetime cigarettes and now smoking on all or some days. Participants must also reside in the metro Washington, DC area. The first portion ...

Phase N/A

Testing an Organizational Change Model to Address Smoking in Mental Healthcare

Despite an overall reduction in US smoking rates from >50% in the 1960s to about 20% by 2000, the rate of smoking among persons with a serious mental illness (SMI) remains 2-3 times greater than in the general population. Transforming the mental healthcare system to integrate and adhere to evidence-based ...

Phase N/A

Women's Initiative Supporting Health Increasing Healthcare Access

The PI identified two priority needs of RR women: (1) adequate HIV/HCV prevention counseling and services, including HIV pre-exposure prophylaxis (PrEP) medications for women at high risk, and (2) primary care as an avenue to address co-occurring SUD, MH disorders, and trauma that interfere with HIV preventive care. WISH is ...

Phase N/A

Neural Mechanisms Associated With Risk of Smoking Relapse

Smoking is the greatest preventable cause of mortality and a significant economic burden. Even with the best available treatments, most smokers relapse within days or weeks after a quit attempt. Nicotine replacement therapy, the most widely used pharmacotherapy, yields end of treatment quit rates of <25% suggesting that managing nicotine ...

Phase N/A

Computer-Assisted Brief Intervention

Four out of five youth in the juvenile justice system show evidence of being under the influence during their offenses, and over half test positive for substances at the time of their arrest. Further, 92% of arrested juveniles who tested positive for drugs tested positive for marijuana. Although some treatment ...

Phase N/A

N-acetylcysteine for Tobacco Use Disorder

The aim of this study is to assess the effects of N-acetylcysteine (NAC) on initial cessation and relapse prevention in adult cigarette smokers. Specifically, this study has the following aims: Aim 1) Examine the efficacy of NAC, compared to placebo, in helping smokers achieve three days of continuous abstinence; Aim ...

Phase

Manipulating Tobacco Constituents in Male Menthol Smokers

The FDA has the regulatory authority to reduce, but not eliminate, nicotine from cigarettes. The Tobacco Products Scientific Advisory Committee has noted, among other things, that removal of menthol cigarettes from the marketplace would benefit the public health. A parent study (NCT02048852) examines the potential impact of these two regulatory ...

Phase N/A

Manipulating Tobacco Constituents in Female Menthol Smokers

Study is designed to address the following questions that have been outlined by the FDA as particular areas of interest: What are the factors, including menthol and other flavorings that influence the appeal of tobacco products to vulnerable populations: What is the impact of these factors on cessation, switching tobacco ...

Phase N/A

Cannabidiol and Cocaine Craving/Dependence

The investigators will carry out a double-blind, randomized, parallel-group, placebo-controlled trial to assess the effects of 92 days of CBD 400 mg (for the first 2 days starting on Day 2 of the study) or 800 mg (subjects who report side effects with the 800mg dose will be administered the ...

Phase